Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Brain on the Neurotransmitter Binding

Effect of rTMS Over Primary Motor Cortex on Gamma-aminobutyric Acid A (GABAA)-[18F]Flumazenil Binding: A Positron Emission Tomography (PET) Study

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01819675

Enrollment

Registered

2013-03-27

Start date

2013-03-31

Completion date

2016-02-29

Last updated

2017-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Hemiplegia

Keywords

Neuronal plasticity, Neurotransmitter agents, Receptors, neurotransmitter, Transcranial magnetic stimulation, Stroke, gamma-Aminobutyric Acid

Brief summary

The purpose of this study is to determine whether repetitive transcranial magnetic stimulation (rTMS) over the brain can modulate the binding of neurotransmitter (GABA in this study) to its receptor using the special PET study.

Detailed description

Repetitive transcranial magnetic stimulation (rTMS) can modulate the excitability of cortex but exact mechanism is not well determined in human-beings. Changes in some neurotransmitters' status in brain after rTMS have been suggested as a possible mechanism, but role of GABA is not clear. Twelve healthy people will be recruited. They will receive the rTMS over the primary motor cortex of the dominant hand. Individual subject will receive three sessions of rTMS with wash-out period (more than 3 days) between the rTMS sessions. Three rTMS sessions are high frequency (10Hz), low frequency (1Hz) and sham rTMS. The order of rTMS sessions will be randomly decided. After completing each rTMS session, \[18F\]flumazenil-PET will be checked. The purpose of this study is to investigate 1)whether rTMS over the primary motor cortex can modulate the \[18F\]flumazenil binding potential and 2)whether the modulation of \[18F\]flumazenil binding potential by rTMS can be different according to the applied frequency of rTMS.

Interventions

DEVICELow frequency rTMS

DEVICEHigh frequency rTMS

DEVICESham rTMS

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy people * 18-50 yrs old * Right handedness * Written informed consent

Exclusion criteria

* Previous medical diseases such as seizure, stroke, diabetes, hypertension. * Taking any drugs * Smoker * Pregnancy * Contraindication of PET or MRI * Stroke or any tumor in MRI * Metals objects in the head or eyes * Cardiac pacemaker or cochlear implant

Design outcomes

Primary

Measure	Time frame	Description
[18F]flumazenil binding potential	up to 3 months	Immediately after rTMS session , PET image will be acquired. By using these images, \[18F\]flumazenil binding potential will be calculated in selected anatomical region up to 3 months

Secondary

Measure	Time frame	Description
Purdue pegboard test score	Before rTMS (baseline) and average 2hours after rTMS	evaluation for hand function

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026